CoChat

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors

Open access
Kluger, Harriet M., Zito, Christopher R., Turcu, Gabriela, Baine, Marina K., Zhang, Hongyi, Adeniran, Adebowale, Sznol, Mario, Rimm, David L., Kluger, Yuval, Chen, Lieping, Cohen, Justine V., Jilaveanu, Lucia B. · 2017 · Clinical Cancer Research
Cited by 152

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Purpose: With recent approval of inhibitors of PD-1 in melanoma, non–small cell lung cancer (NSCLC) and renal cell carcinoma, extensive efforts are under way to develop biomarkers predictive of response. PD-L1 expression has been most widely studied, and is more predictive in NSCLC than renal cell carcinoma or melanoma. We therefore studied differences in expression patterns across tumor types. Experimental Design: We used tissue microarrays with tumors from NSCLC, renal cell carcinoma, or melanoma and a panel of cell lines to study differences between tumor types. Predictive studies were conducted on samples from 65 melanoma patients treated with PD-1 inhibitors alone or with CTLA-4 inhibitors, characterized for outcome. PD-L1 expression was studied by quantitative immunofluorescence using two well-validated antibodies. Results: PD-L1 expression was higher in NSCLC specimens than renal cell carcinoma, and lowest in melanoma (P = 0.001), and this finding was confirmed in a panel of cell lines. In melanoma tumors, PD-L1 was expressed either on tumor cells or immune-infiltrating cells. The association between PD-L1 expression in immune-infiltrating cells and progression-free or overall-survival in melanoma patients treated with ipilimumab and nivolumab was stronger than PD-L1 expression in tumor cells, and remained significant on multivariable analysis. Conclusions: PD-L1 expression in melanoma tumor cells is lower than NSCLC or renal cell carcinoma cells. The higher response rate in melanoma patients treated with PD-1 inhibitors is likely related to PD-L1 in tumor-associated inflammatory cells. Further studies are warranted to validate the predictive role of inflammatory cell PD-L1 expression in melanoma and determine its biological significance. Clin Cancer Res; 23(15); 4270–9. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-3146

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 1×

    “Inhibitors of PD-1 or its ligand, PD-L1, have similarly been studied in advanced melanoma and other tumor types, and have now been approved for a number of diseases including melanoma, renal cell carcinoma (RCC), bladder cancer, non-small cell lung cancer (NSCLC), head and neck cancer and Hodgkin’s lymphoma (4-12).”
    Background
  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

    Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

    Self-citation
  • PD-1 blockade induces responses by inhibiting adaptive immune resistance

    Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×

    “Presence of CD8þ T cells at the periphery of the melanoma tumor bed is associated with a greater likelihood of response to PD-1 inhibitors, as is presence of tumor specificMHCclass IImolecules (19, 20).”
    Background
  • Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

    Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 2×

    “Cut-points for positivity as high as 50% have been used in some lung cancer studies (11).”
    BackgroundMethod
  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×

    “Clinical trials using PD-L1 or PD-1 inhibitors have used a variety cut-points to determine "positive" versus "negative" expression, ranging from as low as 1% in the phase III trial of nivolumab versus everolimus in renal cell carcinoma, in which 75% of patients had <1% tumor expression to as high as 50% in the phase I…”
    Background
  • Nivolumab in Previously Untreated Melanoma without BRAF Mutation

    Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 2×

    “Inhibitors of PD-1 or its ligand, PD-L1, have similarly been studied in advanced melanoma and other tumor types, and have now been approved for a number of diseases including melanoma, renal cell carcinoma (RCC), bladder cancer, non-small cell lung cancer (NSCLC), head and neck cancer and Hodgkin’s lymphoma (4-12).”
    Background
  • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×

    “This is supported by our cell line data, which show that PD-L1 expression in melanoma tumor cells is weak, and by data reported by Herbst and colleagues in multiple tumor types (26).”
    Result
  • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

    Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101

  • Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

    Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

    Self-citation
  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×

    “The first immune checkpoint inhibitor to gain approval, ipilimumab, inhibits CTLA-4 on cytotoxic T cells, resulting in durable responses in 11-19% of patients with advanced melanoma and prolonging overall survival (1-3).”
    Background

Show all 21 references

Cited by

See all 152

Metadata

Authors
Kluger, H. M., Zito, C. R., Turcu, G., Baine, M. K., Zhang, H., Adeniran, A., Sznol, M., Rimm, D. L., Kluger, Y., Chen, L., Cohen, J. V., & Jilaveanu, L. B.
Venue
Clinical Cancer Research
Published
2017-08-01
Volume
23
Issue
15
Pages
4270-4279
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2591239368
Cited by
152
References
21
FWCI
6.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-3146
The paper
Kluger, H. M., Zito, C. R., Turcu, G., Baine, M. K., Zhang, H., Adeniran, A., Sznol, M., Rimm, D. L., Kluger, Y., Chen, L., Cohen, J. V., & Jilaveanu, L. B. (2017). PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-3146

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.